Abstract
More and more evidences have ensured the crucial functions of long non-coding RNAs (lncRNAs) in multiple tumors. It has been discovered that lncRNA-SNHG16 is involved in many tumors. Even so, it is still necessary to study SNHG16 comprehensively in bladder cancer. In terms of our study, the level of SNHG16 both in the tumor tissues and cell lines was measured and the relationship among SNHG16, clinicopathological traits and prognosis was explored. Interference assays were applied to determine the biological functions of SNHG16. It was discovered that the level of SNHG16 was evidently enhanced both in tissues and cell lines of bladder cancer. Patients with highly expressed SNHG16 suffered from poor overall survival. Multivariable Cox proportional hazards regression analysis implied that highly expressed SNHG16 could be used as an independent prognostic marker. It could be known from functional assays that silenced SNHG16 impaired cell proliferation, owing to the effects of SNHG16 on cell cycle and apoptosis. Finally, mechanism experiments revealed that SNHG16 could epigenetically silence the expression of p21. The facts above pointed out that lncRNA-SNHG16 might be quite vital for the diagnosis and development of bladder cancer, and could even become an important therapeutic target for bladder cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bansal N, Gupta AK, Gupta A, Sankhwar SN, Mahdi AA. Serum-based protein biomarkers of bladder cancer: A pre- and post-operative evaluation. J Pharm Biomed Anal. 2016;124:22–5.
Racioppi M, D’Agostino D, Totaro A, Pinto F, Sacco E, D’Addessi A, et al. Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. Urol Int. 2012;88:249–58.
Sofra M, Fei PC, Fabrizi L, Marcelli ME, Claroni C, Gallucci M, et al. Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical cystectomy: preliminary results. J Exp Clin Cancer Res. 2013;32:6.
Rose TL, Milowsky MI. Improving systemic chemotherapy for bladder cancer. Curr Oncol Rep. 2016;18:27.
Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting non-coding RNAs in disease. J Clin Invest. 2017;127:761–71.
Chandra Gupta S, Nandan Tripathi Y. Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer. 2016;140:1955–67.
Deng H, Zhang J, Shi J, Guo Z, He C, Ding L, et al. Role of long non-coding RNA in tumor drug resistance. Tumour Biol. 2016;37:11623–31.
Ning L, Li Z, Wei D, Chen H, Yang C. LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma. Cancer Biomark. 2017;19:75–83.
Wu ZJ, Li Y, Wu YZ, Wang Y, Nian WQ, Wang LL, et al. Long non-coding RNA CCAT2 promotes the breast cancer growth and metastasis by regulating TGF-beta signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21:706–14.
Xiao JN, Yan TH, Yu RM, Gao Y, Zeng WL, Lu SW, et al. Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression. J Cancer Res Clin Oncol. 2017;143:981–90.
Zhang S, Wang Y, Chen M, Sun L, Han J, Elena VK, et al. CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma. Sci Rep. 2017;7:44033.
Chen X, Gao G. Long noncoding RNA PVT1 as a novel diagnostic biomarker and therapeutic target for melanoma. Biomed Res Int. 2017;2017:7038579.
Cai C, Huo Q, Wang X, Chen B, Yang Q. SNHG16 contributes to breast cancer cell migration by competitively binding miR-98 with E2F5. Biochem Biophys Res Commun. 2017;485:272–8.
Christensen LL, True K, Hamilton MP, Nielsen MM, Damas ND, Damgaard CK, et al. SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol. 2016;10:1266–82.
Duan W, Du L, Jiang X, Wang R, Yan S, Xie Y, et al. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer. Oncotarget. 2016;7:78850–8.
Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, et al. LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res. 2016;76:6299–310.
Sun CC, Li SJ, Li G, Hua RX, Zhou XH, Li DJ. Long intergenic noncoding RNA 00511 Acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther Acids. 2016;5:e385.
Hon CC, Ramilowski JA, Harshbarger J, Bertin N, Rackham OJ, Gough J, et al. An atlas of human long non-coding RNAs with accurate 5’ ends. Nature. 2017;543:199–204.
Li W, Li H, Zhang L, Hu M, Li F, Deng J, et al. LINC00672 contributes p53-mediated gene suppression and promotes endometrial cancer chemosensitivity. J Biol Chem 2017;292:5801-13.
Liu JN, Shangguan YM. Long non-coding RNA CARLo-5 upregulation associates with poor prognosis in patients suffering gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21:530–4.
Wang TH, Chan CW, Fang JY, Shih YM, Liu YW, Wang TV, et al. 2-O-Methylmagnolol upregulates the long non-coding RNA, GAS5, and enhances apoptosis in skin cancer cells. Cell Death Dis. 2017;8:e2638.
Zhang H, Xiong Y, Xia R, Wei C, Shi X, Nie F. The pseudogene-derived long noncoding RNA SFTA1P is down-regulated and suppresses cell migration and invasion in lung adenocarcinoma. Tumour Biol. 2017;39:1010428317691418.
Li T, Meng XL, Yang WQ. Long noncoding RNA PVT1 acts as a “sponge” to inhibit microRNA-152 in gastric cancer cells. Digest Dis Sci. 2017;62:3021–28.
Li Y, Wu Z, Yuan J, Sun L, Lin L, Huang N, et al. Long non-coding RNA MALAT1 promotes gastric cancer tumorigenicity and metastasis by regulating vasculogenic mimicry and angiogenesis. Cancer Lett 2017;395:31–44.
Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–14.
Acknowledgements
We thank the laboratory members.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest
Additional information
Xianxiang Cao and Jing Xu authors are contributed equally to this manuscript.
Rights and permissions
About this article
Cite this article
Cao, X., Xu, J. & Yue, D. LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer. Cancer Gene Ther 25, 10–17 (2018). https://doi.org/10.1038/s41417-017-0006-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41417-017-0006-x
This article is cited by
-
SNHG18 inhibits bladder cancer cell proliferation by increasing p21 transcription through destabilizing c-Myc protein
Cancer Cell International (2023)
-
The value of urinary exosomal lncRNA SNHG16 as a diagnostic biomarker for bladder cancer
Molecular Biology Reports (2023)
-
LncRNA SNHG16 contributes to osteosarcoma progression by acting as a ceRNA of miR-1285-3p
BMC Cancer (2021)
-
Coding the noncoding: 2 years of advances in the field of microRNAs and long noncoding RNAs
Cancer Gene Therapy (2021)
-
Joint changes in RNA, RNA polymerase II, and promoter activity through the cell cycle identify non-coding RNAs involved in proliferation
Scientific Reports (2021)